{
    "organizations": [],
    "uuid": "8a41186458c005665886b2dd45babbf8b2c6ddc5",
    "author": "",
    "url": "https://www.reuters.com/article/brief-caladrius-biosciences-acquires-exc/brief-caladrius-biosciences-acquires-exclusive-worldwide-rights-to-data-set-regulatory-filings-for-cd34-cell-therapy-program-idUSASB0C8YA",
    "ord_in_thread": 0,
    "title": "BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6, 2018 / 1:04 PM / in 11 minutes BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program Reuters Staff 1 Min Read March 6 (Reuters) - Caladrius Biosciences Inc: * CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA * CALADRIUS BIOSCIENCES INC - UNDER DEAL TERMS , ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS TO DATA SET, REGULATORY FILINGS FOR CD34+ CELL THERAPY PROGRAM * CALADRIUS BIOSCIENCES INC - IN EXCHANGE, SHIRE WILL RECEIVE UNDISCLOSED UP-FRONT CONSIDERATION, MILESTONES AND A ROYALTY ON PRODUCT SALES * CALADRIUS BIOSCIENCES INC - ACQUIRED FROM SHIRE PLC AN EXCLUSIVE WORLDWIDE LICENSE TO DATA FROM A LATE STAGE CD34+ CELL THERAPY PROGRAM Source text for Eikon: Further company coverage:",
    "published": "2018-03-06T15:03:00.000+02:00",
    "crawled": "2018-03-06T15:19:59.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "minute",
        "bioscience",
        "acquires",
        "exclusive",
        "worldwide",
        "right",
        "data",
        "set",
        "regulatory",
        "filing",
        "cell",
        "therapy",
        "program",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "caladrius",
        "bioscience",
        "inc",
        "caladrius",
        "bioscience",
        "acquires",
        "exclusive",
        "license",
        "late",
        "stage",
        "cell",
        "therapy",
        "program",
        "treatment",
        "refractory",
        "angina",
        "caladrius",
        "bioscience",
        "inc",
        "deal",
        "term",
        "acquired",
        "exclusive",
        "worldwide",
        "right",
        "data",
        "set",
        "regulatory",
        "filing",
        "cell",
        "therapy",
        "program",
        "caladrius",
        "bioscience",
        "inc",
        "exchange",
        "shire",
        "receive",
        "undisclosed",
        "consideration",
        "milestone",
        "royalty",
        "product",
        "sale",
        "caladrius",
        "bioscience",
        "inc",
        "acquired",
        "shire",
        "plc",
        "exclusive",
        "worldwide",
        "license",
        "data",
        "late",
        "stage",
        "cell",
        "therapy",
        "program",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}